Is this a Prime Time To acquire Purple Biotech Ltd ADR (PPBT) stock

In the latest session, Purple Biotech Ltd ADR (NASDAQ: PPBT) closed at $0.67 up 9.66% from its previous closing price of $0.61. In other words, the price has increased by $+0.0500 from its previous closing price. On the day, 98816 shares were traded. PPBT stock price reached its highest trading level at $0.6700 during the session, while it also had its lowest trading level at $0.6200.

Ratios:

For a deeper understanding of Purple Biotech Ltd ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.20 and its Current Ratio is at 2.20. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PPBT now has a Market Capitalization of 17.60M and an Enterprise Value of 2.54M.

Stock Price History:

Over the past 52 weeks, PPBT has reached a high of $2.16, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 0.7151, while the 200-Day Moving Average is calculated to be 1.0449.

Shares Statistics:

For the past three months, PPBT has traded an average of 100.46K shares per day and 86.59k over the past ten days. A total of 25.94M shares are outstanding, with a floating share count of 25.75M. Insiders hold about 0.75% of the company’s shares, while institutions hold 11.01% stake in the company. Shares short for PPBT as of Mar 15, 2024 were 223k with a Short Ratio of 2.22, compared to 315.36k on Feb 15, 2024.

Earnings Estimates

There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.19 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.21, while EPS last year was -$0.33. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.15 and low estimates of -$0.23.

Analysts are recommending an EPS of between -$0.9 and -$0.93 for the fiscal current year, implying an average EPS of -$0.91. EPS for the following year is -$0.63, with 3 analysts recommending between -$0.46 and -$0.96.

Most Popular